| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchases of property and equipment | 590 | 590 |
| Net cash provided by (used in) investing activities | 138,828 | 86,575 |
| Proceeds from exercise of stock options and warrants | 3 | - |
| Net cash provided by financing activities | 3 | - |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 36,460 | 16,499 |
| Cash and cash equivalents at beginning of period | 59,820 | - |
| Cash and cash equivalents at end of period | 96,280 | - |
Astria Therapeutics, Inc. (ATXS)
Astria Therapeutics, Inc. (ATXS)